Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 12890-12900

  González Santamaría, José ^a   Campagna, Michela ^a   García, María Angel ^a,b   Marcos Villar, Laura ^a   González, Dolores ^a   Gallego, Pedro ^a   Lopitz Otsoa, Fernando ^c   Guerra, Susana ^a,d   Rodríguez, Manuel S ^c,e   Esteban, Mariano ^a   Rivas, Carmen ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PUMA PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VACCINIA VIRUS E3 PROTEIN; VIRUS PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SUMOYLATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; VACCINIA VIRUS;

CELL LINE; DOWN-REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RNA-BINDING PROTEINS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMO-1 PROTEIN; UBIQUITINATION; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE FACTORS;

VACCINIA VIRUS;

EID: 84855823939     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05628-11     Document Type: Article

References (71)

1. Ahn, J. H., Y. Xu, W. J. Jang, M. J. Matunis, and G. S. Hayward. 2001. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 75:3859-3872.
2. Beattie, E., et al. 1996. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 12:89-94.
3. Beattie, E., E. Paoletti, and J. Tartaglia. 1995. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology 210:254-263.
4. Berndt, A., H. Hofmann-Winkler, N. Tavalai, G. Hahn, and T. Stamminger. 2009. Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J. Virol. 83:12881-12894.
5. Bernier-Villamor, V., D. A. Sampson, M. J. Matunis, and C. D. Lima. 2002. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108:345-356.
6. Blomster, H. A., et al. 2009. Novel proteomics strategy brings insight into the prevalence of SUMO-2 target sites. Mol. Cell. Proteomics 8:1382-1390.
7. Blomster, H. A., et al. 2010. In vivo identification of sumoylation sites by a signature tag and cysteine-targeted affinity purification. J. Biol. Chem. 285:19324-19329.
8. Boggio, R., and S. Chiocca. 2006. Viruses and sumoylation: recent highlights. Curr. Opin. Microbiol. 9:430-436.
9. Brandt, T. A., and B. L. Jacobs. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75:850-856.
10. Campagna, M., et al. SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ. 18:72-79.
11. Canning, M., C. Boutell, J. Parkinson, and R. D. Everett. 2004. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J. Biol. Chem. 279:38160-38168.
12. Chang, H. W., and B. L. Jacobs. 1993. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194:537-547.
13. Chang, H. W., L. H. Uribe, and B. L. Jacobs. 1995. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69:6605-6608.
14. Chang, H. W., J. C. Watson, and B. L. Jacobs. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, doublestranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 89:4825-4829.
15. Demirov, D. G., A. Ono, J. M. Orenstein, and E. O. Freed. 2002. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc. Natl. Acad. Sci. U. S. A. 99:955-960.
16. Desterro, J. M., M. S. Rodriguez, and R. T. Hay. 1998. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 2:233-239.
17. Domingo-Gil, E., E. Perez-Jimenez, I. Ventoso, J. L. Najera, and M. Esteban. 2008. Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections. J. Virol. 82:254-267.
18. Eladad, S., et al. 2005. Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum. Mol. Genet. 14:1351-1365.
19. Everett, R. D., et al. 1997. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519-1530.
20. Garcia, M. A., S. Guerra, J. Gil, V. Jimenez, and M. Esteban. 2002. Antiapoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21:8379-8387.
21. Garrus, J. E., et al. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
22. Geiss-Friedlander, R., and F. Melchior. 2007. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8:947-956.
23. Geoffroy, M. C., and R. T. Hay. 2009. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat. Rev. Mol. Cell Biol. 10:564-568.
24. Golebiowski, F., et al. 2009. System-wide changes to SUMO modifications in response to heat shock. Sci. Signal. 2:ra24.
25. Guerra, S., A. Caceres, K. P. Knobeloch, I. Horak, and M. Esteban. 2008. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 4:e1000096.
26. Guo, D., et al. 2004. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat. Genet. 36:837-841.
27. Hecker, C. M., M. Rabiller, K. Haglund, P. Bayer, and I. Dikic. 2006. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281:16117-16127.
28. Hofmann, H., S. Floss, and T. Stamminger. 2000. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J. Virol. 74:2510-2524.
29. Hsiao, H. H., E. Meulmeester, B. T. Frank, F. Melchior, and H. Urlaub. 2009. "ChopNSpice," a mass spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-conjugated peptides. Mol. Cell. Proteomics 8:2664-2675.
30. Isaacson, M. K., and H. L. Ploegh. 2009. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5:559-570.
31. Jentsch, S., and G. Pyrowolakis. 2000. Ubiquitin and its kin: how close are the family ties? Trends Cell Biol. 10:335-342.
32. Kerscher, O. 2007. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 8:550-555.
33. Kuo, H. Y., et al. 2005. SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc. Natl. Acad. Sci. U. S. A. 102:16973-16978.
34. Kwon, J. A., and A. Rich. 2005. Biological function of the vaccinia virus Z-DNA-binding protein E3L: gene transactivation and antiapoptotic activity in HeLa cells. Proc. Natl. Acad. Sci. U. S. A. 102:12759-12764.
35. Langland, J. O., and B. L. Jacobs. 2002. The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology 299:133-141.
36. Langland, J. O., et al. 2006. Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J. Virol. 80:10083-10095.
37. Langland, J. O., S. M. Pettiford, and B. L. Jacobs. 1995. Nucleic acid affinity chromatography: preparation and characterization of double-stranded RNA agarose. Protein Expr. Purif 6:25-32.
38. Lee, H. R., and J. H. Ahn. 2004. Sumoylation of the major immediate-early IE2 protein of human cytomegalovirus Towne strain is not required for virus growth in cultured human fibroblasts. J. Gen. Virol. 85:2149-2154.
39. Lee, S. B., and M. Esteban. 1994. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology 199:491-496.
40. Li, M., et al. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416:648-653.
41. Lin, D. Y., et al. 2006. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24:341-354.
42. Ludwig, H., et al. 2005. Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: regulation of the virus life cycle and identification of differentially expressed host genes. J. Virol. 79:2584-2596.
43. Marcos-Villar, L., et al. 2009. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J. Virol. 83:8849-8858.
44. Matic, I., et al. 2008. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell. Proteomics 7:132-144.
45. Matunis, M. J., X. D. Zhang, and N. A. Ellis. 2006. SUMO: the glue that binds. Dev. Cell 11:596-597.
46. Meulmeester, E., et al. 2005. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18:565-576.
47. Minty, A., X. Dumont, M. Kaghad, and D. Caput. 2000. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J. Biol. Chem. 275:36316-36323.
48. Nerenberg, B. T., et al. 2005. The poxviral RING protein p28 is a ubiquitin ligase that targets ubiquitin to viral replication factories. J. Virol. 79:597-601.
49. Palacios, S., et al. 2005. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its selfassociation. Mol. Biol. Cell 16:2822-2835.
50. Peng, J., et al. 2003. A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21:921-926.
51. Pickart, C. M., and D. Fushman. 2004. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 8:610-616.
52. Rivas, C., J. Gil, Z. Melkova, M. Esteban, and M. Diaz-Guerra. 1998. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 243:406-414.
53. Rogan, S., and S. Heaphy. 2000. The vaccinia virus E3L protein interacts with SUMO-1 and ribosomal protein L23a in a yeast two hybrid assay. Virus Genes 21:193-195.
54. Rosendorff, A., et al. 2004. EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 78:367-377.
55. Sampson, D. A., M. Wang, and M. J. Matunis. 2001. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276:21664-21669.
56. Satheshkumar, P. S., L. C. Anton, P. Sanz, and B. Moss. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
57. Sharp, T. V., et al. 1998. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. Virology 250:302-315.
58. Shen, T. H., H. K. Lin, P. P. Scaglioni, T. M. Yung, and P. P. Pandolfi. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
59. Song, J., L. K. Durrin, T. A. Wilkinson, T. G. Krontiris, and Y. Chen. 2004. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. U. S. A. 101:14373-14378.
60. Takahashi, H., S. Hatakeyama, H. Saitoh, and K. I. Nakayama. 2005. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J. Biol. Chem. 280:5611-5621.
61. Tatham, M. H., et al. 2001. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276:35368-35374.
62. Teale, A., et al. 2009. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J. Virol. 83:2099-2108.
63. Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-798.
64. van Buuren, N., B. Couturier, Y. Xiong, and M. Barry. 2008. Ectromelia virus encodes a novel family of F-box proteins that interact with the SCF complex. J. Virol. 82:9917-9927.
65. van der Knaap, J. A., et al. 2005. GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Mol. Cell 17:695-707.
66. Verger, A., J. Perdomo, and M. Crossley. 2003. Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 4:137-142.
67. Versteeg, G. A., et al. 2010. Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein. J. Virol. 84:5423-5430.
68. Vertegaal, A. C., et al. 2006. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell. Proteomics 5:2298-2310.
69. Watson, J. C., H. W. Chang, and B. L. Jacobs. 1991. Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase. Virology 185:206-216.
70. Yasuda, J., M. Nakao, Y. Kawaoka, and H. Shida. 2003. Nedd4 regulates egress of Ebola virus-like particles from host cells. J. Virol. 77:9987-9992.
71. Yuwen, H., J. H. Cox, J. W. Yewdell, J. R. Bennink, and B. Moss. 1993. Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 195:732-744.